Skip to main content
SpringerLink
Log in

Cytokine and Angiogenesis Inhibitors

  • Chapter
Urological Cancers

  • 379 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Jemal A, et al. Cancer statistics, 2002. CA Cancer J Clin 2002;52(1):23–47.

    PubMed  Google Scholar 

  2. Motzer RJ, Bander NH, Nanus DM. Renal-cell carcinoma. N Engl J Med 1996;335(12):865–875.

    Article  PubMed  CAS  Google Scholar 

  3. Dhote R, et al. Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 2000;86(1):20–27.

    Article  PubMed  CAS  Google Scholar 

  4. Yagoda A, Abi-Rached B, Petrylak D. Chemotherapy for advanced renal-cell carcinoma: 1983–1993. Semin Oncol 1995;22(1):42–60.

    PubMed  CAS  Google Scholar 

  5. Elson PJ, Witte RS, Trump DL. Prognostic factors for survival in patients with recurrent or metastatic renal cell carcinoma. Cancer Res 1988;48(24 pt 1):7310–7313.

    PubMed  CAS  Google Scholar 

  6. Palmer PA, et al. Prognostic factors for survival in patients with advanced renal cell carcinoma treated with recombinant interleukin-2. Ann Oncol 1992;3(6):475–480.

    PubMed  CAS  Google Scholar 

  7. Jones M, et al. The impact of interleukin-2 on survival in renal cancer: a multivariate analysis. Cancer Biother 1993;8(4):275–288.

    PubMed  CAS  Google Scholar 

  8. Fossa SD, Kramar A, Droz JP. Prognostic factors and survival in patients with metastatic renal cell carcinoma treated with chemotherapy or interferon-alpha. Eur J Cancer 1994;30A(9):1310–1314.

    Article  PubMed  CAS  Google Scholar 

  9. Motzer RJ, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999;17(8):2530–2540.

    PubMed  CAS  Google Scholar 

  10. Motzer RJ, et al. Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma. J Clin Oncol 2004;22(3):454–463.

    Article  PubMed  Google Scholar 

  11. Motzer RJ, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear-cell histology. J Clin Oncol 2002;20(9):2376–2381.

    Article  PubMed  Google Scholar 

  12. Kudoh S, et al. Defective granzyme B gene expression and lytic response in T lymphocytes infiltrating human renal cell carcinoma. J Immunother 1997;20(6):479–487.

    PubMed  CAS  Google Scholar 

  13. Ulchaker J, et al. Interferon-gamma production by T lymphocytes from renal cell carcinoma patients: evidence of impaired secretion in response to interleukin-12. J Immunother 1999;22(1):71–79.

    PubMed  CAS  Google Scholar 

  14. Almand B, et al. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001;166(1):678–689.

    PubMed  CAS  Google Scholar 

  15. Finke JH, et al. Tumor-infiltrating lymphocytes in patients with renal-cell carcinoma. Ann N Y Acad Sci 1988;532:387–394.

    PubMed  CAS  Google Scholar 

  16. Van Den Eynde BJ, et al. A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. J Exp Med 1999;190(12):1793–1800.

    Article  Google Scholar 

  17. Motzer RJ, et al. Effect of cytokine therapy on survival for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(9):1928–1935.

    PubMed  CAS  Google Scholar 

  18. Negrier S, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Francais d’Immunotherapie. Ann Oncol 2002;13(9):1460–1468.

    Article  PubMed  CAS  Google Scholar 

  19. Van Poppel H, Baert L. Nephrectomy for metastatic renal cell carcinoma and surgery for distant metastases. Acta Urol Belg 1996;64(2):11–17.

    PubMed  Google Scholar 

  20. Piltz S, et al. Long-term results after pulmonary resection of renal cell carcinoma metastases. Ann Thorac Surg 2002;73(4):1082–1087.

    Article  PubMed  Google Scholar 

  21. Le Francois D, et al. Evolution of cell-mediated immunity in mice bearing tumors produced by a mammary carcinoma cell line. Influence of tumor growth, surgical removal, and treatment with irradiated tumor cells. J Natl Cancer Inst 1971;46(5):981–987.

    PubMed  Google Scholar 

  22. Whitney RB, Levy JG, Smith AG. Influence of tumor size and surgical resection on cell-mediated immunity in mice. J Natl Cancer Inst 1974;53(1):111–116.

    PubMed  CAS  Google Scholar 

  23. Dadian G, et al. Immunological parameters in peripheral blood of patients with renal cell carcinoma before and after nephrectomy. Br J Urol 1994;74(1):15–22.

    Article  PubMed  CAS  Google Scholar 

  24. Pantuck AZA, Shvarts O, Gitlitz B, deKernion J, Figlin R, Belldegrun A. Natural history and the role of nephrectomy in the biology of RCC: the UCLA experience. Proc Am Soc Clin Oncol 2000;19:1348.

    Google Scholar 

  25. Flanigan RC, et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med 2001;345(23):1655–1659.

    Article  PubMed  CAS  Google Scholar 

  26. Mickisch GH, et al. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 2001;358(9286):966–970.

    Article  PubMed  CAS  Google Scholar 

  27. Flanigan RC, et al. Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 2004;171(3):1071–1076.

    Article  PubMed  Google Scholar 

  28. Naitoh J, et al. Metastatic renal cell carcinoma with concurrent inferior vena caval invasion: long-term survival after combination therapy with radical nephrectomy, vena caval thrombectomy and postoperative immunotherapy. J Urol 1999;162(1):46–50.

    Article  PubMed  CAS  Google Scholar 

  29. Lineham WM, et al. Cancer of the kidney and ureter. In: Devita VT, ed. Cancer: Principles and Practice of Oncology. Philadephia: Lippincott Williams and Wilkins, 1997:1271–1300.

    Google Scholar 

  30. Motzer RJ, et al. Phase II trial of branched peg interferon-alpha 2a (40 kDa) for patients with advanced renal cell carcinoma. Ann Oncol 2002;13(11):1799–1805.

    Article  PubMed  CAS  Google Scholar 

  31. Bukowski, R, et al. Pegylated interferon alfa-2b treatment for patients with solid tumors: a phase I/II study. J Clin Oncol 2002;20(18):3841–3849.

    Article  PubMed  CAS  Google Scholar 

  32. Interferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trial. Medical Research Council Renal Cancer Collaborators. Lancet 1999;353(9146):14–17.

    Article  Google Scholar 

  33. Hancock B, Griffiths G, Ritchie A, et al., on behalf of the MRC Renal Cancer Collaborators. Updated results of the MRC randomised controlled trial of alpha interferon vs. MPA in patients with metastatic renal carcinoma. Proc Am Soc Clin Oncol 2000;abstract 1336.

    Google Scholar 

  34. Coppin C, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2000(3):CD001425.

    Google Scholar 

  35. Hoffman AD, et al. Expression of retinoic acid receptor beta in human renal cell carcinomas correlates with sensitivity to the antiproliferative effects of 13-cis-retinoic acid. Clin Cancer Res 1996;2(6):1077–1082.

    PubMed  CAS  Google Scholar 

  36. Motzer RJ, et al. Interferon alfa-2a and 13-cis-retinoic acid in renal cell carcinoma: antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995;13(8):1950–1957.

    PubMed  CAS  Google Scholar 

  37. Motzer RJ, et al. Phase III trial of interferon alfa-2a with or without 13-cis-retinoic acid for patients with advanced renal cell carcinoma. J Clin Oncol 2000;18(16):2972–2980.

    PubMed  CAS  Google Scholar 

  38. Gleave ME, et al. Interferon gamma-1b compared with placebo in metastatic renal-cell carcinoma. Canadian Urologic Oncology Group. N Engl J Med 1998;338(18):1265–1271.

    Article  PubMed  CAS  Google Scholar 

  39. De Mulder PH, et al. EORTC (30885) randomised phase III study with recombinant interferon alpha and recombinant interferon alpha and gamma in patients with advanced renal cell carcinoma. The EORTC Genitourinary Group. Br J Cancer 1995;71(2):371–375.

    PubMed  Google Scholar 

  40. Fyfe G, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13(3):688–696.

    PubMed  CAS  Google Scholar 

  41. Fisher RI, Rosenberg SA, Fyfe G. Long-term survival update for high-dose recombinant interleukin-2 in patients with renal cell carcinoma. Cancer J Sci Am 2000;6(suppl 1):S55–57.

    PubMed  Google Scholar 

  42. Yang JC, et al. Randomized comparison of high-dose and low-dose intravenous interleukin-2 for the therapy of metastatic renal cell carcinoma: an interim report. J Clin Oncol 1994;12(8):1572–1576.

    PubMed  CAS  Google Scholar 

  43. Yang JC, et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003;21(16):3127–3132.

    Article  PubMed  CAS  Google Scholar 

  44. Bukowski RM. Natural history and therapy of metastatic renal cell carcinoma: the role of interleukin-2. Cancer 1997;80(7):1198–1220.

    Article  PubMed  CAS  Google Scholar 

  45. Lindsey KR, Rosenberg SA, Sherry RM. Impact of the number of treatment courses on the clinical response of patients who receive high-dose bolus interleukin-2. J Clin Oncol 2000;18(9):1954–1959.

    PubMed  CAS  Google Scholar 

  46. Rosenberg SA, et al. Prospective randomized trial of high-dose interleukin-2 alone or in conjunction with lymphokine-activated killer cells for the treatment of patients with advanced cancer. J Natl Cancer Inst 1993;85(8):622–632.

    PubMed  CAS  Google Scholar 

  47. Figlin RA, et al. Treatment of metastatic renal cell carcinoma with nephrectomy, interleukin-2 and cytokine-primed or CD8(+) selected tumor infiltrating lymphocytes from primary tumor. J Urol 1997;158(3 Pt 1):740–745.

    Article  PubMed  CAS  Google Scholar 

  48. Figlin RA, et al. Multicenter, randomized, phase III trial of CD8(+) tumor-infiltrating lymphocytes in combination with recombinant interleukin-2 in metastatic renal cell carcinoma. J Clin Oncol 1999;17(8):2521–2529.

    PubMed  CAS  Google Scholar 

  49. Sherry RM, Rosenberg SA, Yang JC. Relapse after response to interleukin-2-based immunotherapy: patterns of progression and response to retreatment. J Immunother 1991;10(5):371–375.

    PubMed  CAS  Google Scholar 

  50. Negrier S, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Francais d’Immunotherapie. N Engl J Med 1998;338(18):1272–1278.

    Article  PubMed  CAS  Google Scholar 

  51. Escudier B, et al. Cytokines in metastatic renal cell carcinoma: is it useful to switch to interleukin-2 or interferon after failure of a first treatment? Groupe Francais d’Immunotherape. J Clin Oncol 1999;17(7):2039–2043.

    PubMed  CAS  Google Scholar 

  52. Motzer RJ, et al. Randomized multicenter phase II trial of subcutaneous recombinant human interleukin-12 versus interferon-alpha 2a for patients with advanced renal cell carcinoma. J Interferon Cytokine Res 2001;21(4):257–263.

    Article  PubMed  CAS  Google Scholar 

  53. Lissoni P, et al. In vivo stimulation of IL-12 secretion by subcutaneous low-dose IL-2 in metastatic cancer patients. Br J Cancer 1998;77(11):1957–1960.

    PubMed  CAS  Google Scholar 

  54. Pyrhonen S, et al. Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer. J Clin Oncol 1999;17(9):2859–2867.

    PubMed  CAS  Google Scholar 

  55. Fossa SD, et al. Recombinant interferon alfa-2a with or without vinblastine in metastatic renal cell carcinoma: results of a European multicenter phase III study. Ann Oncol 1992;3(4):301–305.

    PubMed  CAS  Google Scholar 

  56. Murphy BR, et al. A phase II trial of interferon alpha-2A plus fluorouracil in advanced renal cell carcinoma. A Hoosier Oncology Group study. Invest New Drugs 1992;10(3):225–230.

    Article  PubMed  CAS  Google Scholar 

  57. Atzpodien J, et al. Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 1993;29A(suppl 5):S6–8.

    Article  PubMed  Google Scholar 

  58. Atzpodien J, et al. IL-2 in combination with IFN-alpha and 5-FU versus tamoxifen in metastatic renal cell carcinoma: long-term results of a controlled randomized clinical trial. Br J Cancer 2001;85(8):1130–1136.

    Article  PubMed  CAS  Google Scholar 

  59. Hofmockel G, et al. Immunochemotherapy for metastatic renal cell carcinoma using a regimen of interleukin-2, interferon-alpha and 5-fluorouracil. J Urol 1996;156(1):18–21.

    Article  PubMed  CAS  Google Scholar 

  60. Joffe JK, et al. A phase II study of interferon-alpha, interleukin-2 and 5-fluorouracil in advanced renal carcinoma: clinical data and laboratory evidence of protease activation. Br J Urol 1996;77(5):638–649.

    PubMed  CAS  Google Scholar 

  61. Ellerhorst JA, et al. Phase II trial of 5-fluorouracil, interferon-alpha and continuous infusion interleukin-2 for patients with metastatic renal cell carcinoma. Cancer 1997;80(11):2128–2132.

    Article  PubMed  CAS  Google Scholar 

  62. Tourani JM, et al. Outpatient treatment with sub-cutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Proleukin Program Cooperative Group. J Clin Oncol 1998;16(7):2505–2513.

    PubMed  CAS  Google Scholar 

  63. Elias L, et al. Infusional interleukin-2 and 5-fluorouracil with subcutaneous interferon-alpha for the treatment of patients with advanced renal cell carcinoma: a southwest oncology group Phase II study. Cancer 2000;89(3):597–603.

    Article  PubMed  CAS  Google Scholar 

  64. Ravaud A, et al. Subcutaneous interleukin-2, interferon alfa-2a, and continuous infusion of fluorouracil in metastatic renal cell carcinoma: a multicenter phase II trial. Groupe Francais d’Immunotherapie. J Clin Oncol 1998;16(8):2728–2732.

    PubMed  CAS  Google Scholar 

  65. Negrier S, et al. Treatment of patients with metastatic renal carcinoma with a combination of subcutaneous interleukin-2 and interferon alfa with or without fluorouracil. Groupe Francais d’Immunotherapie, Federation Nationale des Centres de Lutte Contre le Cancer. J Clin Oncol 2000;18(24):4009–4015.

    PubMed  CAS  Google Scholar 

  66. Smith IE, et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13(2):424–429.

    PubMed  CAS  Google Scholar 

  67. Ahmed FMP, Macfarlane V, Gore M. Infusional chemotherapy (cisplatin, epirubicin, 5-FU: ECF) for patients with epithelial ovarian carcinoma. In: 9th NCI-EORTC Symposium on New Drug Therapy, 1996, Amsterdam.

    Google Scholar 

  68. Allen MJ, et al. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: a phase II study. Br J Cancer 2000;83(8):980–985.

    Article  PubMed  CAS  Google Scholar 

  69. Oevermann K, et al. Capecitabine in the treatment of metastatic renal cell carcinoma. Br J Cancer 2000;83(5):583–587.

    Article  PubMed  CAS  Google Scholar 

  70. Porzsolt F. Adjuvant therapy of renal cell carcinoma with interferon alpha-2a. Proc Am Soc Clin Oncol 1992;11:622.

    Google Scholar 

  71. Trump DL, Elson P, Propert K, et al. Randomized, controlled trial of adjuvant therapy with lymphoblastoid interferon (L-IFN) in resected, high-risk renal cell carcinoma (HR-RCC) Proc Am Soc Clin Oncol 1966;15:253.

    Google Scholar 

  72. Pizzocaro G, et al. Interferon adjuvant to radical nephrectomy in Robson stages II and III renal cell carcinoma: a multicentric randomized study. J Clin Oncol 2001;19(2):425–431.

    PubMed  CAS  Google Scholar 

  73. Clark JI, et al. Adjuvant high-dose bolus interleukin-2 for patients with high-risk renal cell carcinoma: a cytokine working group randomized trial. J Clin Oncol 2003;21(16):3133–3140.

    Article  PubMed  CAS  Google Scholar 

  74. Folkman J. Antiangiogenic therapy. In: Devita VT, ed. Cancer: Principles and Practice of Oncology. Philadephia: Lippincott Williams and Wilkins, 1997.

    Google Scholar 

  75. Modzelewski RA, et al. Isolation and identification of fresh tumor-derived endothelial cells from a murine RIF-1 fibrosarcoma. Cancer Res 1994;54(2):336–339.

    PubMed  CAS  Google Scholar 

  76. Kato T, et al. Enhanced suppression of tumor growth by combination of angiogenesis inhibitor O-(chloroacetyl-carbamoyl)fumagillol (TNP-470) and cytotoxic agents in mice. Cancer Res 1994;54(19):5143–5147.

    PubMed  CAS  Google Scholar 

  77. Teicher BA, et al. Potentiation of cytotoxic cancer therapies by TNP-470 alone and with other anti-angiogenic agents. Int J Cancer 1994;57(6):920–925.

    PubMed  CAS  Google Scholar 

  78. Ingber D, et al. Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumour growth. Nature 1990;348(6301):555–557.

    Article  PubMed  CAS  Google Scholar 

  79. Stadler WM, et al. Multi-institutional study of the angiogenesis inhibitor TNP-470 in metastatic renal carcinoma. J Clin Oncol 1999;17(8):2541–2545.

    PubMed  CAS  Google Scholar 

  80. George DJ, Kaelin WG Jr. The von Hippel-Lindau protein, vascular endothelial growth factor, and kidney cancer. N Engl J Med 2003;349(5):419–421.

    Article  PubMed  Google Scholar 

  81. Yang JC, et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003;349(5):427–434.

    Article  PubMed  CAS  Google Scholar 

  82. Rosen L, Mulay M, Mayers A, et al. Phase I dose-escalating trial of SU5416, a novel angiogenesis inhibitor in patients with advanced malignancies (meeting abstract). Proc Am Soc Clin Oncol 1999;18:618.

    Google Scholar 

  83. Kuenen BC, et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res 2003;9(5):1648–1655.

    PubMed  CAS  Google Scholar 

  84. Gingras D, et al. Matrix proteinase inhibition by AE-941, a multifunctional antiangiogenic compound. Anticancer Res 2001;21(1A):145–155.

    PubMed  CAS  Google Scholar 

  85. Batist G, et al. Neovastat (AE-941) in refractory renal cell carcinoma patients: report of a phase II trial with two dose levels. Ann Oncol 2002;13(8):1259–1263.

    Article  PubMed  CAS  Google Scholar 

  86. O’Reilly MS, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79(2):315–328.

    Article  PubMed  CAS  Google Scholar 

  87. O’Reilly MS, et al. Angiostatin induces and sustains dormancy of human primary tumors in mice. Nat Med 1996;2(6):689–692.

    Article  PubMed  CAS  Google Scholar 

  88. O’Reilly MS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88(2):277–285.

    Article  PubMed  CAS  Google Scholar 

  89. Herbst RS, et al. Phase I study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2002;20(18):3792–3803.

    Article  PubMed  CAS  Google Scholar 

  90. Eisen T, et al. Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer. Br J Cancer 2000;82(4):812–817.

    Article  PubMed  CAS  Google Scholar 

  91. Stebbing J, et al. The treatment of advanced renal cell cancer with high-dose oral thalidomide. Br J Cancer 2001;85(7):953–958.

    Article  PubMed  CAS  Google Scholar 

  92. Motzer RJ, et al. Phase II trial of thalidomide for patients with advanced renal cell carcinoma. J Clin Oncol 2002;20(1):302–306.

    Article  PubMed  CAS  Google Scholar 

  93. Minor DR, et al. A phase II study of thalidomide in advanced metastatic renal cell carcinoma. Invest New Drugs 2002;20(4):389–393.

    Article  PubMed  CAS  Google Scholar 

  94. Escudier B, et al. Phase II trial of thalidomide in renal-cell carcinoma. Ann Oncol 2002;13(7):1029–1035.

    Article  PubMed  CAS  Google Scholar 

  95. Daliani DD, et al. A pilot study of thalidomide in patients with progressive metastatic renal cell carcinoma. Cancer 2002;95(4):758–765.

    Article  PubMed  CAS  Google Scholar 

  96. Corral LG, et al. Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. J Immunol 1999;163(1):380–386.

    PubMed  CAS  Google Scholar 

  97. Richardson PG, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002;100(9):3063–3067.

    Article  PubMed  CAS  Google Scholar 

  98. Nathan PD, Gore ME, Eisen TG. Unexpected toxicity of combination thalidomide and interferon alpha-2a treatment in metastatic renal cell carcinoma. J Clin Oncol 2002;20(5):1429–1430.

    PubMed  CAS  Google Scholar 

  99. Hernberg M, et al. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma. J Clin Oncol 2003;21(20):3770–3776.

    Article  PubMed  CAS  Google Scholar 

  100. Amato R, Schell J, Thompson N, Moore R, Miles B. Phase II study of thalidomide and interleukin-2 in patients with metastatic renal cell carcinoma. Proc Am Soc Clin Oncol 2003;abstract 1556.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Royal Marsden Hospital, London, UK

    Simon Chowdhury MB BS & Martin Gore MB BS, PhD, FRCP

  2. Renal, Melanoma and Lung Units Department of Medicine, Royal Marsden Hospital, London, UK

    Timothy G. Eisen PhD, FRCP

Authors
  1. Simon Chowdhury MB BS
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Timothy G. Eisen PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Martin Gore MB BS, PhD, FRCP
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Faculty of Medicine, Hammersmith Campus, Imperial College London, London, UK

    Jonathan Waxman BSc, MD, FRCP (Professor of Oncology) (Professor of Oncology)

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

Chowdhury, S., Eisen, T.G., Gore, M. (2005). Cytokine and Angiogenesis Inhibitors. In: Waxman, J. (eds) Urological Cancers. Springer, London. https://doi.org/10.1007/1-84628-015-X_17

Download citation

  • DOI: https://doi.org/10.1007/1-84628-015-X_17

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-911-1

  • Online ISBN: 978-1-84628-015-3

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation